I used to work in a high-throughput screening facility. My work was mainly on the lab automation side of things, and as I got more into programming I got recruited into the high-throughput sequencing realm. I enjoyed working in high-throughput screening though, and one thing that intrigued me was all of the hype around virtual high-throughput screening. In theory it sounded great: just model atomic interactions and save the copious amounts of cash required to physically screen a compound library. One postdoc with whom I worked took a job with a company in New Mexico which studied this, but he can't disclose anything he's working on, much to my chagrin.
Anyone care to share their perspective?
1 answer
Hello Dan,
I believe it should be used as a 'companion' method in, e.g., drug discovery / docking analyses, and not as the sole line of evidence on which a drug is developed. Hopefully the FDA agrees with me, but maybe they will not in another few years. It can certainly help to narrow down a list of candidate compounds, thus saving cash, as you implied.
Generally, and more broadly, I am worried that we are relaxing quality control mechanisms that have helped us to grow. There is evidence of this in different sectors.
Kevin
Log in to answer this question.
Changed to
forum